Confidence In SpringWorks Grows With Expanded GSK Deal And Nirogacestat Plans

On Track For First Approval In 2023

 
• By Andrew McConaghie

SpringWorks is on course to bring nirogacestat to market by next year – and could play a pivotal role in making BCMA-targeting drugs a success.

Multiple Myeloma Awareness: Bone marrow aspirate cytology of multiple myeloma, a type of bone marrow cancer of malignant plasma cells, associated with bone pain, bone fractures and anemia.
SpringWork's lead drug is being studied in combination with no fewer than seven BCMA-targeting agents in multiple myeloma. • Source: Shutterstock

More from Archive

More from Scrip